로딩 중…
지수 로딩 중…
STCube, Inc.
052020· KOSDAQ· Information Technology· Technology Hardware & Equipment
₩8,800-4.24%
2026-06-26
Price Chart
STCube, Inc.+29.03%
Financials
Investment Metrics(as of 2026-06-26)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 598.25B KRW |
| Revenue | 6.54B KRW |
| Net Income | -8.74B KRW |
| Total Assets | 83.59B KRW |
| Net Assets | 65.58B KRW |
| Employees | 16 |
| Value | |
| P/B | 9.12x |
| P/S | 91.49x |
| FCF Yield | -3.46% |
| Profitability | |
| ROE | -13.33% |
| ROA | -10.45% |
| Op. Margin | -391.71% |
| Revenue Growth | -24.63% |
| Financial Health | |
| Debt Ratio | 127.47% |
| Total Debt | 0 KRW |
| FCF | -20.68B KRW |
| Cash | 17.66B KRW |
| Current Ratio | 18.71x |
| Performance | |
| 1Y Return | 29.03% |
| 1M Return | -42.03% |
| From 52W High | -60.89% |
| 1Y MDD | -60.18% |
| Trading | |
| Volume | 524,281 shares |
| Foreign Own. | 5.55% |
| Per Share | |
| EPS | -353 KRW |
| BPS | 965 KRW |
Company Info
STCube, established in 1989 and listed on KOSDAQ in 2001, is a diversified company engaged in bio, cosmetics, and IT distribution. In collaboration with STCube Pharmaceuticals, Inc., it develops anti-cancer immunotherapies and conducts cosmetics manufacturing, sales, and distribution under its brand, C-NALS. The company is actively conducting global clinical trials for its innovative new drug, Nelmastobart, and engaging with multinational pharmaceutical companies to strengthen global competitiveness and diversify its drug pipeline. It is headquartered in Gangnam-gu, Seoul.